Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease

Completed · Phase 1

Conditions studied: Anemia, Sickle Cell

In brief

The purpose of this study is to estimate the MTD of Mg pidolate in combination with HU in patients with sickle cell disease who have been on a therapeutic dose (15-30 mg/kg/day) of HU for at least 6 months.

Key facts

Study ID

NCT00143572

Run by

St. Jude Children's Research Hospital

People needed

16

Starts

2004-11-01

Expected to finish

2008-01-01

Last updated by the study team

2017-04-26

Who can join

Age: 3 and older, up to 15. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age > 3 years and < 15 years at the time of study enrollment
• Diagnosis of Hb SS or Hb S beta thalassemia
• Hydroxyurea treatment for at least 6 months prior to study entry at dose of 15 - 30 mg/kg/day
• Compliance with taking HU treatment of at least 70 % for 6 months prior to study entry

You may not qualify if…

• Red blood cell transfusion within the last 3 months resulting in a level of Hb A of 10% or more
• Pregnancy or unwillingness to use effective birth control in sexually active subjects (females who state that they are sexually active)
• Renal dysfunction defined by a serum creatinine greater than 1.5 times the upper limit of normal for age
• Liver dysfunction defined by an ALT greater than twice the upper limit of normal for age
• Concomitant usage of an "antisickling" agent other than hydroxyurea
• Current use of Mg containing drugs
• Iron deficiency, defined by serum ferritin ≤ 10 ng/ml
• Concomitant chronic illness other than sickle cell anemia

Where it is running

• St. Jude Children's Research Hospital — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.